Abstracts tagged "Biologic drugs and tuberculosis"

Abstract Number: 2031 • 2015 ACR/ARHP Annual Meeting
Tuberculosis in Patients Treated with Biological Drugs
Nadia Benzaquén¹, Maria Haye Salinas², Juan Pablo Pirola³, Laura mariela Encinas⁴, Francisco Caeiro⁴, Alejandro J. Alvarellos², Maria Celina de la Vega Sr.⁵, Gustavo Casado⁶, Gimena Gomez Sr.⁷, Gustavo Citera⁸, Maria de los Angeles Gallardo⁹, Ana Quinteros¹⁰, Ida Elena Exeni¹¹, María Alejandra Medina¹², Pablo Astesana¹³, Carolina Sanchez Andia¹⁴, Graciela Gómez¹⁵, Amelia Granel¹⁶, Diana Dubinsky^17,18, Ana Capuccio^19,20, Alicia Eimon⁷, R. Quintana²¹, Bernardo Pons-Estel²², Eduardo Mussano²³, Santiago Scarafia²⁴, Mercedes Argentina García²⁵, Mercedes De La Sota²⁶, Karin Kirmayr²⁷, Edson Javier Velozo²⁸, Sergio Paira²⁹, Ana M. Bertoli³⁰, Cesar Caprarulo³¹, Santiago Aguero³², Cristina Battagliotti³³, Sidney Soares de Souza^34,35, Emilia Cavillion³⁶, A. Perez Davila³⁷, J. C. Barreira³⁸, Maria Larroude^39,40, Francisco Tamaño⁴¹, Alejandra Peluzzoni⁴² and Veronica Saurit⁴, ¹Reumatología, Hospital Privado Centro Médico de Córdoba, Córdoba, Argentina, ²Rheumatology, Hospital Privado de Córdoba, Córdoba, Argentina, ³Servicio de Reumatología, Hospital Privado Centro Médico de Córdoba, Córdoba, Argentina, ⁴Reumatología, Hospital Privado de Córdoba, Córdoba, Argentina, ⁵Hospital Argerich, Buenos Aires, Argentina, ⁶Hospital Militar Central, Buenos Aires, Argentina, ⁷CEMIC, Buenos Aires, Argentina, ⁸Rheumatology, Consultorios Reumatológicos Pampa, Buenos Aires, Argentina, ⁹Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Buenos Aires, Argentina, ¹⁰Centro Integral De Reumatologia, Tucumán, Argentina, ¹¹BALCARCE 462 12F, SANATORIO PARQUE CORDOBA, CORDOBA, Argentina, ¹²Hospital General de Agudos, Ciudad Autónoma de Buenos Aires, Argentina, ¹³Internal Medicine, Unit of Rheumatology, Córdoba, Argentina, ¹⁴Hospital Penna, CABA, Argentina, ¹⁵Rheumatology, Instituto de Investigaciones Medicas Alfredo Lanari, Buenos Aires, Argentina, ¹⁶CALLE 4 no 214, Hospital San Roque De Gonnet, Buenos Aires, Argentina, ¹⁷Hospital de Clinicas, CABA, Argentina, ¹⁸Hospital de Clínicas, Jose de San Martin, Buenos Aires, Argentina, ¹⁹Rheumatology, Hospital cesar Milstein, Buenos Aires, Argentina, ²⁰Hospital Cesar Milstein, CABA, Argentina, ²¹Hospital Provincial, Rosario, Argentina, ²²Sanatorio Parque, Rosario, Argentina, ²³Córdoba, Servicio de Reumatología. Hospital Nacional de Clínicas. Facultad de Ciencias Médicas. Universidad Nacional de Córdoba, Córdoba, Argentina, ²⁴Rheumatology, Hospital Bernardino Rivadavia, Buenos Aires, Argentina, ²⁵Rheumatology Unit, HIGA San Martín, La Plata, Argentina, ²⁶Reumatología, Bahia Blanca, Argentina, ²⁷Centro Bariloche, Río Negro, Argentina, ²⁸Rheumatology, Sanatorio Adventista del Plata, Entre Rios, Argentina, ²⁹Hospital Jose Maria Cullen, Santa Fe, Argentina, ³⁰Reumatología, Clínica Universitaria Reina Fabiola, Córdoba, Argentina, ³¹Reumatologia, French Hospital, Buenos Aires, Argentina, ³²Sanatorio Pasteur, Catamarca, Argentina, ³³Hospital de Niños Dr Orlando Alasia, Santa Fé, Argentina, ³⁴REUMAR, Buenos Aires, Argentina, ³⁵Ramallo 1851, Reumatología, Buenos Aires, Argentina, ³⁶Consultorio, Cordoba, Argentina, ³⁷Rheumatology, Hospital Manuel Rocca, Ciudad Autonoma de Buenos Aires, Argentina, ³⁸Rheumatology, Buenos Aires British Hospital, Buenos Aires, Argentina, ³⁹Tiempo, CABA, Argentina, ⁴⁰Consultorio, Buenos Aires, Argentina, ⁴¹Reumatología, Atención Integral de Reumatología:, Capital Federal, Argentina, ⁴²Hospital Clínica José de San Martín, CABA, Argentina
Background/Purpose: Opportunistic infections are a major risk in with biological drugs therapy, being tuberculosis (TB) one of the most relevant. Objectives: evaluate the frequency of…
Abstract Number: 2041 • 2014 ACR/ARHP Annual Meeting
Performance of a Two-Step Latent Tuberculosis Screening Algorithm in Patients with Rheumatoid Arthritis, Psoriatic Arthritis or Ankylosing Spondylitis Prior to Treatment with Tumor Necrosis Alpha Inhibitors: Prospective Observational Data from the Biorx.Si Registry, 2014 Update
Ziga Rotar¹ and Matija Tomsic^2,3, ¹Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, ²Department of Rheumatology, BioRx.si, University Medical Centre Ljubjana, Ljubljana, Slovenia, ³Faculty of Medicine, Unversity Ljubljana, Ljubljana, Slovenia
Background/Purpose Reactivation of latent tuberculosis infection (LTBI) is a serious concern in patients treated with TNF-α inhibitors (TNFi). Conversely, TB chemoprophylaxis (CP) is time consuming,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].